Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Gemcitabine for the Treatment of Patients with Osteosarcoma

  • Wei, Mei-Yang (Department of Orthopaedics, Fuzhou General Hospital of Nanjing Military Command) ;
  • Zhuang, Yan-Feng (Department of Orthopaedics, Fuzhou General Hospital of Nanjing Military Command) ;
  • Wang, Wan-Ming (Department of Orthopaedics, Fuzhou General Hospital of Nanjing Military Command)
  • Published : 2014.09.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Patients with recurrent or refractory osteosarcoma are considered to have a very poor prognosis, and new regimens are needed to improve the prognosis in this setting. Gemcitabine, a nucleoside antimetabolite, is an analog of deoxycytidine which mainly inhibits DNA synthesis through interfering with DNA chain elongation and depleting deoxynucleotide stores, resulting in gemcitabine-induced cell death. Here we performed a systemic analysis to evaluate gemcitabine based chemotherapy as salvage treatment for patients with recurrent or refractory osteosarcoma. Methods: Clinical studies evaluating the impact of gemcitabine based regimens on response and safety for patients with osteosarcoma were identified by using a predefined search strategy. Pooled response rates (RRs) of treatment were calculated. Results: In gemcitabine based regimens, 4 clinical studies which included 66 patients with recurrent or refractory osteosarcoma were considered eligible for inclusion. Systemic analysis suggested that, in all patients, pooled RR was 12.1% (8/66) in gemcitabine based regimens. Major adverse effects were hematologic toxicity, including grade 3 or 4 anemia, leucopenia and thrombocytopenia in gemcitabine based treatment. No treatment related death occurred in gemcitabine based treatment. Conclusion: This systemic analysis suggests that gemcitabine based regimens are associated with mild activity with good tolerability in treating patients with recurrent or refractory osteosarcoma.

Keywords

References

  1. Bacci G, Picci P, Ferrari S, et al (1993). Primary chemotherapy and delayed surgery for non metastatic osteosarcoma of the extremity: results in 164 patients preoperatively treated with high doses of methotrexate, followed by cisplatin and doxorubicin. Cancer, 72, 1216-26.
  2. Bramwell VH, Burgers M, Sneath R, et al (1992). A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol, 10, 1579-91.
  3. Cao ZQ, Shen Z, Huang WY (2013). MicroRNA-802 promotes osteosarcoma cell proliferation by targeting p27. Asian Pac J Cancer Prev, 14, 7081-4. https://doi.org/10.7314/APJCP.2013.14.12.7081
  4. Chen H, Jiang HZ, Li YC, et al (2014). Antitumor constituents from Anthriscus sylvestris (L.) Hoffm. Asian Pac J Cancer Prev, 15, 2803-7. https://doi.org/10.7314/APJCP.2014.15.6.2803
  5. Diao CY, Guo HB, Ouyang YR, et al (2014). Screening for metastatic osteosarcoma biomarkers with a DNA microarray. Asian Pac J Cancer Prev, 15, 1817-22. https://doi.org/10.7314/APJCP.2014.15.4.1817
  6. Ebeling P, Eisele L, Schuett P, et al (2008). Docetaxel and gemcitabine in the treatment of soft tissue sarcoma-a single-center experience. Onkologie, 31, 11-6.
  7. Fox E1, Patel S, Wathen JK, et al (2012). Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist, 17, 321. https://doi.org/10.1634/theoncologist.2010-0265
  8. Fuchs N, Bielack SS, Epler D, et al (1998). Long-term results of the cooperative German-Austrian-Swiss Osteosarcoma Study Group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol, 9, 893-9. https://doi.org/10.1023/A:1008391103132
  9. Gandhi V, Legha J, Chen F, Hertel LW, Plunkett W (1996). Excision of 20, 20-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA. Cancer Res, 56, 4453-9.
  10. He A1, Qi W, Huang Y, et al (2014). Comparison of pirarubicinbased versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience. Int J Clin Oncol, 18, 498-505.
  11. He JP, Hao Y, Wang XL, et al (2014). Review of the molecular pathogenesis of osteosarcoma. Asian Pac J Cancer Prev, 15, 5967-76. https://doi.org/10.7314/APJCP.2014.15.15.5967
  12. He ML, Wu Y, Zhao JM, et al (2013). PIK3CA and AKT gene polymorphisms in susceptibility to osteosarcoma in a Chinese population. Asian Pac J Cancer Prev, 14, 5117-22. https://doi.org/10.7314/APJCP.2013.14.9.5117
  13. Hensley ML, Maki R, Venkatraman E, et al (2002). Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol, 20, 2824-31. https://doi.org/10.1200/JCO.2002.11.050
  14. Jia J, Tian Q, Liu Y, et al (2013). Interactive effect of bisphenol A (BPA) exposure with -22G/C polymorphism in LOX gene on the risk of osteosarcoma. Asian Pac J Cancer Prev, 14, 3805-8. https://doi.org/10.7314/APJCP.2013.14.6.3805
  15. Jiang W, Huang Y, Wang JP, et al (2013). The synergistic anticancer effect of artesunate combined with allicin in osteosarcoma cell line in vitro and in vivo. Asian Pac J Cancer Prev, 14, 4615-9. https://doi.org/10.7314/APJCP.2013.14.8.4615
  16. Leu KM, Ostruszka LJ, Shewach D, et al (2004). Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol, 22, 1706-12. https://doi.org/10.1200/JCO.2004.08.043
  17. Lin F, Wang Q, Yu W, et al (2011). Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. Asia Pac J Clin Oncol, 7, 270-5. https://doi.org/10.1111/j.1743-7563.2011.01406.x
  18. Maki RG, Wathen JK, Patel SR, et al (2007). Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol, 25, 2755-63. https://doi.org/10.1200/JCO.2006.10.4117
  19. McTiernan A, Whelan JS (2004). A phase II study of docetaxel for the treatment of recurrent osteosarcoma. Sarcoma, 8, 71-6. https://doi.org/10.1155/2004/762736
  20. Mora J, Cruz CO, Parareda A, de Torres C (2009). Treatment of relapsed refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Oncol, 31, 723-9. https://doi.org/10.1097/MPH.0b013e3181b2598c
  21. Nagarajan R, Weigel BJ, Thompson RC, Perentesis JP (2003). Osteosarcoma in the first decade of life. Med Pediatr Oncol, 41, 480-3. https://doi.org/10.1002/mpo.10403
  22. Navid F, Willert JR, McCarville MB, et al (2008). Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer, 113, 419-25. https://doi.org/10.1002/cncr.23586
  23. Okuno S, Edmonson J, Mahoney M, et al (2002). Phase II trial of gemcitabine in advanced sarcomas. Cancer, 94, 3225-9. https://doi.org/10.1002/cncr.10602
  24. Provisor AJ, Ettinger LJ, Nachman JB, et al (1997). Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol, 15, 76-84.
  25. Qi WX1, He AN, Tang LN, et al (2012). Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients. Jpn J Clin Oncol, 42, 427-31. https://doi.org/10.1093/jjco/hys030
  26. Ricotti L, Tesei A, De Paola F, et al (2003). In vitro scheduledependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines. Clin Cancer Res, 9, 900-5.
  27. Ringel I, Horwitz SB (1991). Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst, 83, 288-91. https://doi.org/10.1093/jnci/83.4.288
  28. Seker MM, Seker A, Aksoy S, et al (2014). Clinicopathologic features and prognosis of osteosarcoma in Turkish adults. Asian Pac J Cancer Prev, 15, 3537-40. https://doi.org/10.7314/APJCP.2014.15.8.3537
  29. Song BS, Seo J, Kim DH, et al (2014). Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience. Pediatr Blood Cancer, 61, 1376-81. https://doi.org/10.1002/pbc.25035
  30. Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92, 205-16. https://doi.org/10.1093/jnci/92.3.205
  31. Wang CK, Yu XD, Li Q, et al (2013). Chloroquine and valproic acid combined treatment in vitro has enhanced cytotoxicity in an osteosarcoma cell line. Asian Pac J Cancer Prev, 14, 4651-4. https://doi.org/10.7314/APJCP.2013.14.8.4651
  32. Yang J, Wang ZG, Cai HQ, et al (2013). Effect of variation of ABCB1 and ABCC3 genotypes on the survival of bone tumor cases after chemotherapy. Asian Pac J Cancer Prev, 14, 4595-8. https://doi.org/10.7314/APJCP.2013.14.8.4595

Cited by

  1. Wnt/β-catenin signaling pathway activation reverses gemcitabine resistance by attenuating Beclin1-mediated autophagy in the MG63 human osteosarcoma cell line vol.16, pp.2, 2017, https://doi.org/10.3892/mmr.2017.6828